Immunterápia az urológiai daganatok kezelésében

L. Géczi, A. Ladányi, Tímea Vajdics, Zsófia Küronya, Krisztina Bíró, Fruzsina Gyergyay, Tamás Martin, Krisztián Nagyiványi

Research output: Review article

Abstract

In this clinical review we provide information regarding advance and main achievements in the immunotherapy of genitourinary, particularly renal cell and prostate cancer. Nivolumab treatment became the new standard of care in locally advanced or metastatic renal cell cancer after failure on tyrosine kinase inhibitor treatment. Sipuleucel-T prolonged survival in patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer but had no effect on progression-free survival. Based on the results of phase I/II trials anti-PD-1/PD-L1 monoclonal antibodies are a new hope in the treatment of urothelial bladder cancer. Regarding germ cell tumors basic research is ongoing.

Original languageHungarian
Pages (from-to)41-45
Number of pages5
JournalMagyar Onkologia
Volume60
Issue number1
Publication statusPublished - márc. 2 2016

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Géczi, L., Ladányi, A., Vajdics, T., Küronya, Z., Bíró, K., Gyergyay, F., Martin, T., & Nagyiványi, K. (2016). Immunterápia az urológiai daganatok kezelésében. Magyar Onkologia, 60(1), 41-45.